Reuters logo
BRIEF-Newlink Genetics says Indoximod in combination with Pembrolizumab was well-tolerated
September 7, 2017 / 11:46 AM / 15 days ago

BRIEF-Newlink Genetics says Indoximod in combination with Pembrolizumab was well-tolerated

Sept 7 (Reuters) - Newlink Genetics Corp

* Announced updated data from ongoing phase 2 NLG2103 study of Indoximod, in combination with PD-1 pathway inhibitor, Keytruda

* Indoximod in combination with pembrolizumab was well-tolerated Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below